PD-1/L1 Inhibitor Plus Chemotherapy in the Treatment of Sarcomas

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Sep 8

PMID 36072581

Authors

Zhichao Tian

Weitao Yao

Affiliations

Soon will be listed here.

Abstract

There is an urgent clinical need for new therapeutic regimens for the effective treatment of advanced sarcomas. Accumulating evidence suggests that programmed death receptor-1/programmed death protein ligand-1 (PD-1/L1) inhibitors have synergistic effects with chemotherapy and have been approved for treatment of lung cancer, gastroesophageal cancer, and breast cancer. In this review, we reviewed the synergistic mechanism of PD-1/L1 inhibitors plus chemotherapy in the treatment of cancers, and the application of this combined regimen in several cancers, followed by a summary of the current evidence on the application of this combined regimen in the treatment of sarcomas as well as the main clinical trials currently underway. Based on the findings of this review, we believe that this combined approach will play an important role in the treatment of some subtypes of sarcomas in the future.

Citing Articles

Combining nanoparticle albumin-bound paclitaxel with camrelizumab in advanced soft tissue sarcoma: activity, safety, and future perspectives.

Tian Z, Feng Y, Yang Y, Liu X, Qu G, Yang Y Front Pharmacol. 2024; 15:1335054.

PMID: 38362151 PMC: 10867195. DOI: 10.3389/fphar.2024.1335054.

Chemotherapeutic drugs for soft tissue sarcomas: a review.

Tian Z, Yao W Front Pharmacol. 2023; 14:1199292.

PMID: 37637411 PMC: 10450752. DOI: 10.3389/fphar.2023.1199292.

Immunotherapy Plus Radiotherapy for the Treatment of Sarcomas: Is There a Potential for Synergism?.

Wang J, Ge H, Tian Z Onco Targets Ther. 2023; 16:385-397.

PMID: 37313391 PMC: 10258041. DOI: 10.2147/OTT.S410693.

Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1-positive advanced cervical cancer: a phase II, single-arm study.

An J, Li X, Wang J, Zhu L, An R, Jiang K Front Immunol. 2023; 14:1142256.

PMID: 37153587 PMC: 10161140. DOI: 10.3389/fimmu.2023.1142256.

References

Ma Z, Zhang W, Dong B, Xin Z, Ji Y, Su R . Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. Theranostics. 2022; 12(11):4965-4979. PMC: 9274752. DOI: 10.7150/thno.73152. View

Derosa L, Routy B, Desilets A, Daillere R, Terrisse S, Kroemer G . Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?. Cancer Discov. 2021; 11(10):2396-2412. DOI: 10.1158/2159-8290.CD-21-0236. View

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gumus M, Mazieres J . Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 379(21):2040-2051. DOI: 10.1056/NEJMoa1810865. View

Powles T, Csoszi T, Ozguroglu M, Matsubara N, Geczi L, Cheng S . Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22(7):931-945. DOI: 10.1016/S1470-2045(21)00152-2. View

Galsky M, Arranz Arija J, Bamias A, Davis I, De Santis M, Kikuchi E . Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2020; 395(10236):1547-1557. DOI: 10.1016/S0140-6736(20)30230-0. View

Fukumura D, Kloepper J, Amoozgar Z, Duda D, Jain R . Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018; 15(5):325-340. PMC: 5921900. DOI: 10.1038/nrclinonc.2018.29. View

Gronchi A, Ferrari S, Quagliuolo V, Broto J, Lopez Pousa A, Grignani G . Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial. Lancet Oncol. 2017; 18(6):812-822. DOI: 10.1016/S1470-2045(17)30334-0. View

Ueda M, Ueki K, Kumagai K, Terai Y, Okamoto Y, Ueki M . Apoptosis and tumor angiogenesis in cervical cancer after preoperative chemotherapy. Cancer Res. 1998; 58(11):2343-6. View

Galluzzi L, Humeau J, Buque A, Zitvogel L, Kroemer G . Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020; 17(12):725-741. DOI: 10.1038/s41571-020-0413-z. View

10.

Yamaguchi H, Hsu J, Yang W, Hung M . Mechanisms regulating PD-L1 expression in cancers and associated opportunities for novel small-molecule therapeutics. Nat Rev Clin Oncol. 2022; 19(5):287-305. DOI: 10.1038/s41571-022-00601-9. View

11.

Kong X, Lu P, Liu C, Guo Y, Yang Y, Peng Y . A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review). Mol Med Rep. 2021; 23(5). PMC: 7985997. DOI: 10.3892/mmr.2021.12001. View

12.

Tian Z, Dong S, Yang Y, Gao S, Yang Y, Yang J . Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: a retrospective study. BMC Cancer. 2022; 22(1):56. PMC: 8756702. DOI: 10.1186/s12885-022-09176-1. View

13.

Hall F, Villalobos V, Wilky B . Future directions in soft tissue sarcoma treatment. Curr Probl Cancer. 2019; 43(4):300-307. DOI: 10.1016/j.currproblcancer.2019.06.004. View

14.

Shitara K, Van Cutsem E, Bang Y, Fuchs C, Wyrwicz L, Lee K . Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer: The KEYNOTE-062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020; 6(10):1571-1580. PMC: 7489405. DOI: 10.1001/jamaoncol.2020.3370. View

15.

Yang Z, Zheng R, Zhang S, Zeng H, Li H, Chen W . Incidence, distribution of histological subtypes and primary sites of soft tissue sarcoma in China. Cancer Biol Med. 2019; 16(3):565-574. PMC: 6743618. DOI: 10.20892/j.issn.2095-3941.2019.0041. View

16.

Wang F, Lau J, Yu J . The role of natural killer cell in gastrointestinal cancer: killer or helper. Oncogene. 2020; 40(4):717-730. PMC: 7843415. DOI: 10.1038/s41388-020-01561-z. View

17.

Tawbi H, Burgess M, Bolejack V, Van Tine B, Schuetze S, Hu J . Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol. 2017; 18(11):1493-1501. PMC: 7939029. DOI: 10.1016/S1470-2045(17)30624-1. View

18.

Javed Ansari M, Bokov D, Markov A, Turki Jalil A, Shalaby M, Suksatan W . Cancer combination therapies by angiogenesis inhibitors; a comprehensive review. Cell Commun Signal. 2022; 20(1):49. PMC: 8991477. DOI: 10.1186/s12964-022-00838-y. View

19.

Yi M, Niu M, Xu L, Luo S, Wu K . Regulation of PD-L1 expression in the tumor microenvironment. J Hematol Oncol. 2021; 14(1):10. PMC: 7792099. DOI: 10.1186/s13045-020-01027-5. View

20.

Mackall C, Fleisher T, Brown M, Andrich M, Chen C, Feuerstein I . Distinctions between CD8+ and CD4+ T-cell regenerative pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood. 1997; 89(10):3700-7. View